Tags

Type your tag names separated by a space and hit enter

Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: a meta-analysis.
Front Med China. 2010 Dec; 4(4):457-62.FM

Abstract

This study was performed to determine the prognostic role of preoperative serum carbohydrate antigen (CA) 19-9 levels in the survival of patients with cholangiocarcinoma. Articles published up to June 1(st), 2010 that evaluated preoperative CA19-9 levels and the prognosis of cholangiocarcinoma were collected for meta-analysis. The required information for calculating individual relative risk (RR) was extracted from the studies, and a combined overall RR was estimated. Nine eligible studies were included. One study dealt with extra-hepatic cholangiocarcinoma, while the other eight studies analyzed intra-hepatic cholangiocarcinoma. The mean methodological quality score was 74.1%, ranging from 65.5% to 82.5%. The overall RR for the nine studies was 1.28 (95% confidence interval = 1.10-1.46), and the Z-score for overall effect was 13.83 (P<0.001). The association between serum CA19-9 level and lymph node involvement was also assessed. The combined RR was 1.471 (95% confidence interval = 0.411-5.264) and Z-score for overall effect was 0.59 (P = 0.553). CA19-9 levels were associated significantly with the prognosis of patients with cholangiocarcinoma. This meta-analysis shows that elevation of preoperative CA19-9 levels is correlated with a poor prognosis of patients with cholangiocarcinoma. However, larger scale and randomized studies are needed to draw a more substantive conclusion.

Authors+Show Affiliations

Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis

Language

eng

PubMed ID

21191748

Citation

Liu, Shang-Long, et al. "Serum Carbohydrate Antigen (CA) 19-9 as a Prognostic Factor in Cholangiocarcinoma: a Meta-analysis." Frontiers of Medicine in China, vol. 4, no. 4, 2010, pp. 457-62.
Liu SL, Song ZF, Hu QG, et al. Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: a meta-analysis. Front Med China. 2010;4(4):457-62.
Liu, S. L., Song, Z. F., Hu, Q. G., Shan, D., Hu, S. B., Li, J., & Zheng, Q. C. (2010). Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: a meta-analysis. Frontiers of Medicine in China, 4(4), 457-62. https://doi.org/10.1007/s11684-010-0240-1
Liu SL, et al. Serum Carbohydrate Antigen (CA) 19-9 as a Prognostic Factor in Cholangiocarcinoma: a Meta-analysis. Front Med China. 2010;4(4):457-62. PubMed PMID: 21191748.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: a meta-analysis. AU - Liu,Shang-Long, AU - Song,Zi-Fang, AU - Hu,Qing-Gang, AU - Shan,Duo, AU - Hu,Shao-Bo, AU - Li,Jun, AU - Zheng,Qi-Chang, Y1 - 2010/11/16/ PY - 2010/09/14/received PY - 2010/10/11/accepted PY - 2010/12/31/entrez PY - 2010/12/31/pubmed PY - 2011/5/18/medline SP - 457 EP - 62 JF - Frontiers of medicine in China JO - Front Med China VL - 4 IS - 4 N2 - This study was performed to determine the prognostic role of preoperative serum carbohydrate antigen (CA) 19-9 levels in the survival of patients with cholangiocarcinoma. Articles published up to June 1(st), 2010 that evaluated preoperative CA19-9 levels and the prognosis of cholangiocarcinoma were collected for meta-analysis. The required information for calculating individual relative risk (RR) was extracted from the studies, and a combined overall RR was estimated. Nine eligible studies were included. One study dealt with extra-hepatic cholangiocarcinoma, while the other eight studies analyzed intra-hepatic cholangiocarcinoma. The mean methodological quality score was 74.1%, ranging from 65.5% to 82.5%. The overall RR for the nine studies was 1.28 (95% confidence interval = 1.10-1.46), and the Z-score for overall effect was 13.83 (P<0.001). The association between serum CA19-9 level and lymph node involvement was also assessed. The combined RR was 1.471 (95% confidence interval = 0.411-5.264) and Z-score for overall effect was 0.59 (P = 0.553). CA19-9 levels were associated significantly with the prognosis of patients with cholangiocarcinoma. This meta-analysis shows that elevation of preoperative CA19-9 levels is correlated with a poor prognosis of patients with cholangiocarcinoma. However, larger scale and randomized studies are needed to draw a more substantive conclusion. SN - 1673-7458 UR - https://www.unboundmedicine.com/medline/citation/21191748/Serum_carbohydrate_antigen_(CA)_19-9_as_a_prognostic_factor_in_cholangiocarcinoma:_a_meta-analysis. L2 - https://medlineplus.gov/bileductcancer.html DB - PRIME DP - Unbound Medicine ER -